A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study shows.
A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results